Pilot Studies in Pancreatic Cancer (R03)

The summary for the Pilot Studies in Pancreatic Cancer (R03) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Pilot Studies in Pancreatic Cancer (R03): This funding opportunity is intended to promote innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. Examples of appropriate research areas include, but are not limited to: Identification of genetic aberrations (e.g., mutations, epigenetic changes, etc.) or combinations of aberrations alterations that initiate or promote pancreatic cancer; development of experimental models for human pancreatic cancer to facilitate the understanding of molecular carcinogenesis, to help to identify promising molecular targets, and to test new preventive/therapeutic strategies; exploration of molecular pathways using human cell lines and/or tissues to identify possible novel targets for prevention or therapeutic development; Identification of markers for early detection of cancer; conduct of preclinical studies to identify candidate chemopreventive drug(s) and dietary factors for prevention and to characterize the molecular mechanism(s) of the agent's activity; conduct of small exploratory clinical trials with a potential chemopreventive agent (e.g., a farnesyltransferase inhibitor or a statin) assessing response via endoscopic ultrasound or another similar technology; development of early-stage clinical trials in pancreatic cancer prevention and therapy; assessment of any associations of tumor pathophysiology on tumor development, progression, and preventive/therapeutic response; Conduct of exploratory studies to identify and evaluate biomarkers (with associated assay development) to determine prognosis and predict response to therapy in pancreatic cancer; evaluation of combination therapies for pancreatic cancer; Identification of new' environmental exposures (e.g., adverse energy balance) that may contribute to pancreatic cancer development, including adverse energy balance; assessment of the impact of pancreatic cancer on health-related quality of life of patients and their caregivers; and conduct of pilot surveillance studies and generation of survivorship registries.-Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. -The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. -The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Budgets for direct costs of up to $50,000 per year and a project duration of up to 2 years may be requested for a maximum of $100,000 direct costs over a 2-year project period. -This FOA utilizes the NIH Small Grant (R03) mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-303, which solicits applications under the NIH Exploratory/Developmental Grant (R21) award mechanism. -Eligible organizations include for-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State governments; units of State Tribal governments; units of local governments; units of local Tribal governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs) include any individuals from the applicant institutions who have the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. =Applicants may submit more than one application, provided each application is scientifically distinct.
Federal Grant Title: Pilot Studies in Pancreatic Cancer (R03)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-06-314
Type of Funding: Grant
CFDA Numbers: 93.393
CFDA Descriptions: Cancer Cause and Prevention Research
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Apr 04, 2006
Creation Date: Oct 03, 2007
Archive Date: Oct 07, 2008
Total Program Funding:
Maximum Federal Grant Award: $50,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education City or township governments Private institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) For profit organizations other than small businesses State governments County governments Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply. Faith-based or community-based organizations
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01 Clin...
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Cli...
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Cli...
Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp Cl...
Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include R...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
NIH Directors Transformative Research Award (R01 - Clinical Trial Optional)
NIH Directors New Innovator Award Program (DP2 - Clinical Trial Optional)
Biomarkers Discovery In Parkinsonism (U01 Clinical Trial Optional)
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical...
Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical T...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2018 FederalGrants.com